201. [Fibrinogen/LDL apheresis for treatment of sudden hearing loss: an observational study on 152 patients].
- Author
-
Canis M, Heigl F, Hettich R, Osterkorn D, Osterkorn K, and Suckfuell M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Blood Component Removal methods, Fibrinogen administration & dosage, Hearing Loss, Sudden drug therapy, Lipoproteins, LDL administration & dosage
- Abstract
Disturbances of cochlear microcirculation are among the most discussed causes of sudden sensorineural hearing loss. Increased levels of cholesterol and fibrinogen seem to act as risk factors for inner ear disorders. Fibrinogen/LDL apheresis greatly reduces the concentration of plasma fibrinogen thus leading to improved cochlear blood flow. In a retrospective case series remission rates of 152 patients suffering from sudden sensorineural hearing loss and resistant to former treatment were investigated after treatment with a single apheresis. Complete remission was reported in 11% of patients, partial remission in 43%. 37% had no change of hearing threshold and 2% reported a decrease in hearing. Rates of complete remissions decreased from 22% within the first 2 weeks after onset of hearing loss to 14% after 6 weeks. In the same period of time rates of partial remissions decreased from 33% to 13%. The present study shows that apheresis achieved complete or partial remission in 54% of patients even after unsuccessful treatment with another therapy and the therapeutic window lies by approximately 6 weeks.
- Published
- 2008
- Full Text
- View/download PDF